Thus, it could be expected that joint pharmacological inhibition of PI3K/AKT/mTOR together with Cn inhibition in T-ALL could effectively deplete putative LICs contributing to improved clinical response and reduced risk of relapse. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.